The ₹81 buyer. The ₹90 minority.

The price reset nobody should ignore

The government moved from a market-influenced reserve to independent appraisal and a new bid.

Primary event and official disclosures; labels identify where data are illustrative.

The official Cabinet release reconstructs a failed initial process: a ₹94.42 reserve price was set against an impacted quoted-market reference, while the earlier unimpacted pre-EoI market price in October 2022 was ₹42.40. Ahead of January 2026 bids the stock was ₹108.12. Initial bids were below reserve and were rejected. The government subsequently invited improved offers, with shares at ₹70.38 before 18 May 2026 best-offer bidding.

This is a price-discovery experiment, not a simple sale at a permanent fair-value marker. A high public quote had influenced the first reserve, yet the bid process did not clear. The state then prioritised an independent valuation anchor. A minority holder treating ₹81 as a guaranteed tender floor is making an unsupported legal and economic assumption.

Require the definitive sale agreement and independent legal confirmation of any mandatory offer, exemptions, escrow, lock-ins and timing. RBI fit-and-proper compliance is not the same thing as a fully completed acquisition.

The government says independent agencies used market-multiple and asset-valuation methodologies; the average of their assessments was ₹75.99 per share. The winning ₹81 bid exceeded both individual independent appraisals. The release states the cited share price was volatile over a ₹61.01–₹118.38 valuation-period range and was disregarded for valuation.

₹52,878.0806 crore for 60.72% at ₹81 implies about 1,075.3 crore shares outstanding and ₹87,080 crore total transaction-implied equity value, subject to rounded percentages. At the ₹90.44 market reference, total equity capitalisation is roughly ₹97,250 crore — about ₹10,170 crore greater. This is a valuation gap, not distributable cash.

The government accepted a bid above its documented benchmark despite a higher contemporaneous stock price. The appropriate question is not “why sell cheaply?” alone, but which pricing methods, market liquidity and post-control economics explain the difference. The government expressly described narrowly traded price volatility.

Who owns IDBI after the proposed sale?

Percentage of total shares; regulatory approval and close remain conditions.

The central government sells 30.48 percentage points and LIC 30.24, leaving 15% and 19% respectively. The government says both will withdraw board nominees and become public shareholders. It has authority for later open-market sales of its residual 15%; LIC may manage its residual position subject to regulators. The successful buyer must submit regulatory compliance plans.

Fairfax-backed ownership can bring strategic control, while roughly one-third of shares remain in government/LIC hands. Potential future float, governance transitions and regulatory ownership constraints create a different economic claim from the block purchased by the controlling investor.

The government FAQ is authoritative for the approved transaction decision; it is not a substitute for a signed SPA or an expert legal opinion on minority exit rights. We do not represent the ₹81 consideration as an open-offer entitlement.

IDBI reported FY26 net interest income of ₹13,512 crore, down from ₹14,626 crore in FY25 (-7.6%). Yet reported PAT increased from ₹7,515 crore to ₹9,513 crore (+26.6%). Non-interest income rose to ₹6,746 crore from ₹4,924 crore (+37.0%). FY26 NIM declined from 4.56% to 3.77%: a 79-basis-point compression.

The ₹1,114-crore reduction in NII and ₹1,998-crore increase in PAT create a ₹3,112-crore directional gap requiring explanations in non-interest income, provision/recovery, expense and tax lines. Rising profit does not prove recurring net-interest franchise strength. This observation alone is not evidence of improper accounting.

A buyer can create value by normalising liability costs, improving branch/fee productivity and deploying surplus capital. But any forecast assuming FY26 PAT growth persists mechanically overstates confidence until recurring PPOP and expected credit costs are reconstructed.

March 2026 deposits were ₹3,47,163 crore, net advances ₹2,53,626 crore, net worth ₹55,749 crore and CASA ₹1,54,816 crore. The CASA ratio slipped to 44.59% from 46.55%. CET1 was 25.56%; GNPA 2.32% and NNPA 0.15%. The credit/deposit ratio advanced to 73.06%.

High CET1 is a reservoir of optionality and a burden on average shareholder equity simultaneously. Loan growth adds book earnings only when incremental after-tax spread net of through-cycle loss and operating cost exceeds the capital charge. The right peer lens is risk-adjusted ROE, not simply private versus public ownership.

Each 10bp margin change on an illustrative ₹3 lakh crore average earning-asset base moves annualised pretax net-interest income by ₹300 crore. The base is deliberately illustrative, not a disclosed average earning-asset balance. Different deposit beta and asset-mix assumptions can reverse this benefit.

Reported FY26 ROA was 2.27%, ROE 18.93%, EPS ₹8.85 and reported book value approximately ₹51.85 per share using the transaction-implied share count. A market quote of ₹90.44 is roughly 1.74x this FY26 equity, compared with approximately 1.56x at ₹81.

The multiple is supportable only if market participants expect durable post-normalisation ROE above the cost of equity. Compare return on tangible common equity, recurring fee contribution, marginal funding cost, new-loan vintage credit loss and needed reinvestment, not the control narrative.

Larger franchise deposit competition, legacy operational rigidity, high technology expense and subsequent state/LIC share sales can prevent convergence to efficient private-bank economics even if Fairfax adds management resources.

The entity designated strategic buyer is 10955230 Canada Inc., with Fairfax Financial Holdings as parent. The state/LIC residual shares remain meaningful after the proposed sale. Government and LIC nominee withdrawal is explicitly contemplated in the public announcement.

A serious governance review must map the exact acquisition vehicle, voting/board agreements, related-party banking exposure, capital raising, CEO succession, compensation alignment and future sale restrictions. Without these terms, the report cannot adjudicate minority rights.

A post-close board change accompanied by falling CASA, growing credit cost or weak technology execution would show that ownership substitution has not delivered incremental bank economics.

At ₹90.44, a three-year 18% price CAGR would require approximately ₹148.6 before dividends; the calendar to March 2029 is about 2.46 years, demanding a shorter-period terminal price of approximately ₹136.0 on the same annual hurdle. At 1.5x exit P/B, even ₹136 requires roughly ₹90.7 book value per share; at 2.0x, ₹68.0. These are mechanical expectations, not predicted outcomes.

Our scenario explorer grows FY26 equity from ₹55,749 crore by retaining part of scenario ROE; divides by the reverse-implied 1,075.3 crore shares; then applies explicit terminal P/B. Distributions are estimated separately. It does not project wholesale balance-sheet repricing or undisclosed merger synergies.

An investable variant must be an independently supportable forecast of post-credit-cost ROE, deposit growth and dividend policy whose terminal price clears the hurdle. The control price is not the stock’s intrinsically correct future price.

Near term: signed SPA and RBI roadmap, Q2 FY27 bank NIM and CASA, cash/recoveries split, management responsibilities, future government/LIC disposal terms. FY28: quality of incremental lending, recurring PPOP, cost-to-income and branch productivity. FY29: ROE after seasoning new-loan cohorts and shareholder distributions.

Acquisition cancellation or material repricing; legally adverse minority treatment; sustained NIM compression with weak CASA; material new slippages or poor credit costs; ROE materially below cost of equity after normalisation; unanticipated dilution.

A definitive judgment on minority treatment cannot be made without the SPA and legal opinion. Full FY26 annual footnotes, Q1/Q2 granular credit-cost schedules and management assurance history were not comprehensively reconciled here.

Rebuild the FY29 shareholder outcome

All controls are analyst-defined sensitivities, not disclosed guidance. The calculation is deliberately transparent and excludes unverified adjustments identified below.

Full research passage index

Every chapter’s research passages are reproduced here for editorial desk audit and easy extraction.